| 2007 JASN IMPACT FACTOR 7.111 | HOME AUTHOR INFO EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP | |||
| CURRENT ISSUE | ARCHIVES | JASN Express | ONLINE SUBMISSION | |

*Renal Division, Department of Clinical Medicine, Faculty of Medicine, University of São Paulo, São Paulo, Brazil; and
Department of Pharmacology, Faculty of Medical Sciences, University of Campinas, Campinas, Brazil.
Correspondence to Dr. Roberto Zatz, Laboratório de Fisiopatologia Renal, Av. Dr. Arnaldo, 455, 3-s/3342, 01246-903 São Paulo SP, Brazil. Phone: 55-11-3068-9428; Fax: 55-11-3083-1693; E-mail: rzatz{at}usp.br
ABSTRACT. The functional role of the NO synthase (NOS) isoforms in the normal or diseased kidney is uncertain. This study examined the renal expression of the endothelial (eNOS), neuronal (nNOS), and inducible (iNOS) isoforms by both immunohistochemistry and Western blot analyses in sham-operated rats (S) and in rats subjected to 5/6 nephrectomy (Nx). Primary antibodies from two different sources were used to detect iNOS. Additional S and Nx rats were chronically treated with aminoguanidine (AG), a selective iNOS inhibitor. All three isoforms were clearly expressed in S kidney. Their renal abundance, evaluated by Western blot analysis, fell in Nx rats. With the use of anti-iNOS antibodies from two distinct sources, the immunohistochemical analysis showed the presence of what appeared to be two distinct iNOS fractions: a "tubular" fraction, present in S and with decreased intensity in Nx; and an "interstitial" fraction, observed only in inflamed areas of Nx rats. AG treatment greatly attenuated renal injury in Nx rats by a direct antiinflammatory effect, likely related to iNOS inhibition, rather than to amelioration of renal hemodynamics or to reduced protein glycation. These observations suggest that: (1) the functional role of the renal iNOS isoform may vary dramatically under different physiologic conditions; (2) caution should be taken in the interpretation of immunohistochemical iNOS data, because antibodies from different sources may detect different iNOS fractions; and (3) AG treatment may become useful in the treatment of human progressive nephropathies, even those not associated with diabetes or aging.
This article has been cited by other articles:
![]() |
B. Piotrkowski, C. G. Fraga, and E. M. V. de Cavanagh Mitochondrial function and nitric oxide metabolism are modified by enalapril treatment in rat kidney Am J Physiol Regulatory Integrative Comp Physiol, April 1, 2007; 292(4): R1494 - R1501. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Bautista-Garcia, L. G. Sanchez-Lozada, M. Cristobal-Garcia, E. Tapia, V. Soto, Ma. C. Avila-Casado, R. Marquez-Velasco, R. Bojalil, M. Franco, and J. Herrera-Acosta Chronic inhibition of NOS-2 ameliorates renal injury, as well as COX-2 and TGF-{beta}1 overexpression in 5/6 nephrectomized rats Nephrol. Dial. Transplant., November 1, 2006; 21(11): 3074 - 3081. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Rodriguez-Gomez, R. Wangensteen, J. M. Moreno, V. Chamorro, A. Osuna, and F. Vargas Effects of chronic inhibition of inducible nitric oxide synthase in hyperthyroid rats Am J Physiol Endocrinol Metab, June 1, 2005; 288(6): E1252 - E1257. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Erdely, G. Freshour, C. Smith, K. Engels, J. L. Olson, and C. Baylis Protection against puromycin aminonucleoside-induced chronic renal disease in the Wistar-Furth rat Am J Physiol Renal Physiol, July 1, 2004; 287(1): F81 - F89. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Erdely, L. Wagner, V. Muller, A. Szabo, and C. Baylis Protection of Wistar Furth Rats from Chronic Renal Disease Is Associated with Maintained Renal Nitric Oxide Synthase J. Am. Soc. Nephrol., October 1, 2003; 14(10): 2526 - 2533. [Abstract] [Full Text] [PDF] |
||||
|
HOME
CURRENT ISSUE
ARCHIVES
JASN Express
ONLINE SUBMISSION
AUTHOR INFO
EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP |
Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673